Chemotherapy-induced Nausea and Vomiting
Conditions
Keywords
prevalence, chemotherapy-induced nausea and vomiting, oncology, suportive care
Brief summary
This study evaluates the prevalence of delayed chemotherapy induced nausea in adult oncology patients in real clinical practice of day clinics.
Detailed description
Chemotherapies are rated to have a high to minimal emetogenic potential in oncology patients. Their potential to induce delayed nausea is supposed to often be higher than their emetogenic potential. However, data on delayed chemotherapy-related nausea are scarce, which is problematic because nausea (a) has a large impact on patients quality of life and treatment decisions, (b) is often underestimated by health care professionals, (c) is less responsive to commonly used antiemetic medication, and (d) may even be different from rates that have been established in controlled clinical trials. Therefore, the aim of this study is to assess the prevalence of delayed chemotherappy-induced nausea in adult oncology patients in dayclinics.
Interventions
None listed
Sponsors
ZETUP St. Gallen
Dr.-Hans-Altschüler-Stiftung
University Medical Center Freiburg
Spital Thurgau AG
Antje Koller
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* first day of chemotherapy of a new cycle (any cycle) * speak and write German * sign the consent forms
Exclusion criteria
* cognitive or linguistic impairments that would significantly impede consent or participation (as assessed by the nurses in charge) * accompanying radiotherapy; * pre-existing nausea within three days before the start of the first chemotherapy in this cycle; and * prior participation in CINrate (each person participates only once)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| delayed Nausea | Each patient: each days for 5 days after chemotherapy; recruitment: six weeks | nausea that occurs 24 hours to 5 days after chemotherapy (100mm VAS in diary) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| acute and delayed vomiting | Each patient: each day for 5 days after chemotherapy; recruitment: six weeks | vomiting that occurs within 5 days of chemotherapy (100mm VAS in diary) |
| adherence to antiemetics | Each patient: each day for 5 days after chemotherapy; recruitment: six weeks | prescribed antiemetics compared with taken antiemetics; intake is calculated in % of the correct dose (dosing adherence) and in % of the dose at the right time (timing adherence) |
| acute nausea | Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks | nausea that occurs within 24 hours of chemotherapy (100mm VAS in diary) |
| interference of nausea or vomiting with everyday life | Each patient: measured at day 5 after chemotherapy; recruitment: six weeks | Functional Living Index Cancer (FLIE) |
| patient-related barriers to antiemetics | Each patient: measured at day 5 after chemotherapy; recruitment: six weeks | Nausea and Vomiting Management Barriers Questionnaire (NVMBQ) |
| antiemetic prescription | Each patient: at day of chemotherapy at discharge from dayclinic; recruitment: six weeks | antiemetic medication that is prescribed |
Countries
Switzerland
Outcome results
None listed